These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 10202025)

  • 1. Host B7-1 and B7-2 costimulatory molecules contribute to the eradication of B7-1-transfected P815 tumor cells via a CD8+ T cell-dependent mechanism.
    La Motte RN; Sharpe AH; Bluestone JA; Mokyr MB
    J Immunol; 1999 Apr; 162(8):4817-23. PubMed ID: 10202025
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Importance of B7-1-expressing host antigen-presenting cells for the eradication of B7-2 transfected P815 tumor cells.
    La Motte RN; Sharpe AH; Bluestone JA; Mokyr MB
    J Immunol; 1998 Dec; 161(12):6552-8. PubMed ID: 9862681
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Involvement of altered B7 expression in dioxin immunotoxicity: B7 transfection restores the CTL but not the autoantibody response to the P815 mastocytoma.
    Prell RA; Kerkvliet NI
    J Immunol; 1997 Mar; 158(6):2695-703. PubMed ID: 9058803
    [TBL] [Abstract][Full Text] [Related]  

  • 4. B7-1 but not B7-2 efficiently costimulates CD8+ T lymphocytes in the P815 tumor system in vitro.
    Gajewski TF
    J Immunol; 1996 Jan; 156(2):465-72. PubMed ID: 8543795
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antitumor immunity elicited by tumor cells transfected with B7-2, a second ligand for CD28/CTLA-4 costimulatory molecules.
    Yang G; Hellström KE; Hellström I; Chen L
    J Immunol; 1995 Mar; 154(6):2794-800. PubMed ID: 7533183
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Importance of the B7-2 molecule for low dose melphalan-induced acquisition of tumor-eradicating immunity by mice bearing a large MOPC-315 tumor.
    Mokyr MB; Kalinichenko TV; Gorelik L; Bluestone JA
    J Immunol; 1998 Feb; 160(4):1866-74. PubMed ID: 9469448
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rejection of MHC class II-transfected tumor cells requires induction of tumor-encoded B7-1 and/or B7-2 costimulatory molecules.
    Baskar S; Clements VK; Glimcher LH; Nabavi N; Ostrand-Rosenberg S
    J Immunol; 1996 May; 156(10):3821-7. PubMed ID: 8621919
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor rejection requires a CTLA4 ligand provided by the host or expressed on the tumor: superiority of B7-1 over B7-2 for active tumor immunization.
    Gajewski TF; Fallarino F; Uyttenhove C; Boon T
    J Immunol; 1996 Apr; 156(8):2909-17. PubMed ID: 8609411
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The capacity of the natural ligands for CD28 to drive IL-4 expression in naïve and antigen-primed CD4+ and CD8+ T cells.
    Bian Y; Hiraoka S; Tomura M; Zhou XY; Yashiro-Ohtani Y; Mori Y; Shimizu J; Ono S; Dunussi-Joannopoulos K; Wolf S; Fujiwara H
    Int Immunol; 2005 Jan; 17(1):73-83. PubMed ID: 15569772
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Heterogeneous effects of B7-1 and B7-2 in the induction of both protective and therapeutic anti-tumor immunity against different mouse tumors.
    Martin-Fontecha A; Cavallo F; Bellone M; Heltai S; Iezzi G; Tornaghi P; Nabavi N; Forni G; Dellabona P; Casorati G
    Eur J Immunol; 1996 Aug; 26(8):1851-9. PubMed ID: 8765031
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antitumor effect of CD40 ligand: elicitation of local and systemic antitumor responses by IL-12 and B7.
    Nakajima A; Kodama T; Morimoto S; Azuma M; Takeda K; Oshima H; Yoshino S; Yagita H; Okumura K
    J Immunol; 1998 Aug; 161(4):1901-7. PubMed ID: 9712059
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Specificity and longevity of antitumor immune responses induced by B7-transfected tumors.
    Townsend SE; Su FW; Atherton JM; Allison JP
    Cancer Res; 1994 Dec; 54(24):6477-83. PubMed ID: 7527298
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential requirement for CD4 help in the development of an antigen-specific CD8+ T cell response depending on the route of immunization.
    Bour H; Horvath C; Lurquin C; Cerottini JC; MacDonald HR
    J Immunol; 1998 Jun; 160(11):5522-9. PubMed ID: 9605156
    [TBL] [Abstract][Full Text] [Related]  

  • 14. B7.1 is a quantitatively stronger costimulus than B7.2 in the activation of naive CD8+ TCR-transgenic T cells.
    Fields PE; Finch RJ; Gray GS; Zollner R; Thomas JL; Sturmhoefel K; Lee K; Wolf S; Gajewski TF; Fitch FW
    J Immunol; 1998 Nov; 161(10):5268-75. PubMed ID: 9820499
    [TBL] [Abstract][Full Text] [Related]  

  • 15. B7-negative versus B7-positive P815 tumor: differential requirements for priming of an antitumor immune response in lymph nodes.
    Yang G; Mizuno MT; Hellström KE; Chen L
    J Immunol; 1997 Jan; 158(2):851-8. PubMed ID: 8993003
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human fibroblasts transduced with CD80 or CD86 efficiently trans-costimulate CD4+ and CD8+ T lymphocytes in HLA-restricted reactions: implications for immune augmentation cancer therapy and autoimmunity.
    Smythe JA; Fink PD; Logan GJ; Lees J; Rowe PB; Alexander IE
    J Immunol; 1999 Sep; 163(6):3239-49. PubMed ID: 10477593
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogene therapy against mouse leukemia using B7 molecules.
    Takahashi T; Hirano N; Takahashi T; Chiba S; Yazaki Y; Hirai H
    Cancer Gene Ther; 2000 Jan; 7(1):144-50. PubMed ID: 10678367
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 4-1BBL cooperates with B7-1 and B7-2 in converting a B cell lymphoma cell line into a long-lasting antitumor vaccine.
    Guinn BA; DeBenedette MA; Watts TH; Berinstein NL
    J Immunol; 1999 Apr; 162(8):5003-10. PubMed ID: 10202049
    [TBL] [Abstract][Full Text] [Related]  

  • 19. B7-1/CD80-transduced tumor cells elicit better systemic immunity than wild-type tumor cells admixed with Corynebacterium parvum.
    Chen L; McGowan P; Ashe S; Johnston JV; Hellström I; Hellström KE
    Cancer Res; 1994 Oct; 54(20):5420-3. PubMed ID: 7522958
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Disruption of CD154:CD40 blocks generation of allograft immunity without affecting APC activation.
    Shepherd DM; Kerkvliet NI
    J Immunol; 1999 Sep; 163(5):2470-7. PubMed ID: 10452982
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.